Prothena Corp (PRTA) 47.75 $PRTA Prothena Reports

New Post Public Reply Private Reply Replies (0) Message Board

Jun 10, 2016 at 1:22 PM

Prothena Corp (PRTA) 47.75 $PRTA

Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases
Globe Newswire - Thu Jun 09, 3:05PM CDT
- All doses of PRX003 found to be safe and well tolerated, meeting the primary objective of the Phase 1 single ascending dose study in healthy volunteers
PRTA: 47.75 (+0.34)

Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis
Globe Newswire - Mon May 23, 3:05PM CDT
- New clinical data to be presented from expansion cohort of Phase 1/2 trial of NEOD001 for the potential treatment of AL amyloidosis
PRTA: 47.75 (+0.34)

Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress
Globe Newswire - Thu May 19, 3:05PM CDT
DUBLIN, Ireland, May 19, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq

RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that data from multiple quality of life studies in patients with AL amyloidosis will be highlighted at The European Hematology Association (EHA) 21st Congress to be held June 9-12 in Copenhagen, Denmark.
PRTA: 47.75 (+0.34)

Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016
Globe Newswire - Mon May 09, 3:05PM CDT
DUBLIN, Ireland, May 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq

RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its Phase 1 single ascending dose study of PRX003 in healthy volunteers will be highlighted in an oral presentation at The European League Against Rheumatism Annual European Congress of Rheumatology (EULAR 2016) to be held June 8-11 in London.
PRTA: 47.75 (+0.34)

Prothena (PRTA) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Wed May 04, 12:00PM CDT
Prothena Corporation plc (PRTA) reported a loss of 81 cents per share in the first quarter of 2016, much wider than both the Zacks Consensus Estimate of a loss of 70 cents.
SHPG: 176.31 (-7.64), PRTA: 47.75 (+0.34), NKTR: 15.95 (-0.33)

Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update
Globe Newswire - Tue May 03, 3:05PM CDT
- Net cash used in operating and investing activities was $25.4 million in the first quarter; strong quarter-end cash position of $474.3 million, including net proceeds of $128.6 million raised through January 2016 public equity offering, supports advancement of multiple clinical development programs
PRTA: 47.75 (+0.34)

Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:04AM CDT
The going has been quite satisfactory as we stand in the thick of the first earnings season of the year.
MACK: 6.36 (-0.20), BIIB: 245.88 (-4.58), ABT: 38.41 (-0.46), JNJ: 116.69 (-0.31), AERI: 18.71 (-0.10), AEGR: 1.39 (-0.11), PRTA: 47.75 (+0.34)

Prothena (PRTA): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 5:42PM CDT
Prothena (PRTA) is expected to report first-quarter 2016 earnings on May 3.
ZTS: 47.46 (-0.68), AGIO: 52.28 (-3.94), PRTA: 47.75 (+0.34)

Data from Prothena's Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid
Globe Newswire - Wed Mar 16, 3:05PM CDT
Antibodies bind specifically to misfolded, non-native forms of transthyretin, disrupting fibril formation
PRTA: 47.75 (+0.34)

Prothena Q4 Loss Narrower than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 10:06AM CST
Prothena (PRTA) reported a loss of 76 cents per share in the fourth-quarter of 2015 on revenues of $0.3 million.
PRTA: 47.75 (+0.34), ANIK: 49.09 (+0.17), CELG: 103.31 (-2.82)

Data From Prothena's Ongoing Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in the Journal of Clinical Oncology
Globe Newswire - Tue Feb 09, 7:10AM CST
Interim Results Previously Presented at Meetings of the American Society for Clinical Oncology and the European Hematology Association
PRTA: 47.75 (+0.34)

Prothena to Report Fourth Quarter and Full Year 2015 Financial Results and Host Webcast Conference Call on February 18
GlobeNewswire - Thu Feb 04, 3:06PM CST
Prothena Corporation plc (Nasdaq

RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quarter and full year 2015 financial results on Thursday, February 18, 2016, after the close of the U.S. financial markets. The announcement will be followed by a live audio webcast and conference call at 4:30 PM ET.
PRTA: 47.75 (+0.34)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Boliden's Q3 2026 Results: What's on the Horizon?

Boliden Ready to Reveal Q3 Numbers Mark it down, folks. Thursday, October 29, 2026, is the day when Boliden's big wigs will step up to the plate and lay their cards on the table about the company's performance over the last quarter. If you've got any skin in this mining powerhouse, you'll want a front-row seat—or at least a virtual one if you're dialing in from...

DIFF Eyewear Opens First Flagship Store in Charleston

DIFF Eyewear: From Clicks to Bricks in Charleston Here's a tale of a brand shaking things up, jumping from the digital stratosphere right into solid ground. DIFF Eyewear has officially planted its flag in Charleston, SC, marking a bold transition from being an exclusively online player to real-world retail. October 10th rang in their first brick-and-mortar store on...

2026 Leica Oskar Barnack Awards Spotlight Global Talent

Winners Redefine Photography's Boundaries in 2026 Photographers are like modern-day storytellers, freezing moments in time and weaving visual narratives that provoke thought—or at least that's what the folks behind the Leica Oskar Barnack Award (LOBA) seem to believe. This year's ceremony upped the ante, not just handing out glittering prizes and shiny cameras, but...

ODL’s Impact Door System Wins 2026 Editors' Pick

Award-Winning Entry: ODL's Latest Triumph In a world where first impressions count, ODL, Inc. sure knows how to leave a mark. Their Impact Rated Fiberglass Entry System with Keystone Frame Technology snagged a notable spot in the 2026 Best of Products Awards by Architect's Newspaper. Let me tell you, in the building biz, accolades like these are no small potatoes. To get...

Zenni and Chase Stokes Foster Student Wellbeing in NYC

Picture this: near 300 high schoolers milling around, glancing through shiny new glasses from the Zenni x Chase Stokes collection. In the heart of New York City, these kids are getting a double-dose of care that's all too rare—free vision screenings paired with mental health support. It's the kind of collaboration that shows you what's possible when a company, an actor,...

Mastering Packaging Costs: Beyond the Box Price

Peeling Back the Layers of Packaging Costs Packaging's a bit like an onion—every layer you peel back reveals another cost you didn’t see at first glance. Folks in the know, like Kyle Reger of Jamestown Container Companies, are flipping the script on how we approach packaging expenses. It's not just about snagging the cheapest box on the shelf anymore. There's a whole...

Greenberg Traurig Nabs Major Award for Sukuk Deal

Legal brands winning awards might seem like just another day in the office, but when a firm like Greenberg Traurig snags the Impact Deal of the Year at the IFLR Middle East Awards, it deserves more than just a shrug. We're talking about a serious feather in the cap for their Capital Markets team, who played a key role in launching Binghatti's hefty USD 1.5 billion Sukuk...

Duke Energy Braces for Isaias: Key Prep Steps Ahead

Brace Yourself: Duke Energy Gears Up for Isaias In the ever-unpredictable game of Mother Nature versus infrastructure, Duke Energy is stepping into the ring once more, readying to tackle potential outages across the Carolinas as Hurricane Isaias edges near. Listen, if there's one thing I've learned over years of watching these weather events unfold on the stock ticker and...

Helio Genomics Shakes Up Liver Cancer Detection Strategy

Rethinking Liver Cancer Detection with HelioLiver Sometimes you stumble upon a tech piece that might genuinely shake up the game. Helio Genomics just poured some serious intel at the San Antonio Liver Cancer Symposium, showcasing how their HelioLiver Dx might outgun traditional scans in sniffing out hepatocellular carcinoma (HCC). They threw down four studies revealing...

Bill Evans Enhances Gateway's Wealth Management Expertise

Welcome Aboard, Bill Evans Some days the financial world throws a gem your way, something worth more than a rat-race racehorse in a shattered stock rally. Meet Bill Evans, a seasoned professional stepping into the vibrant arena of Gateway Financial Partners. He’s put in 29 years around the investment block, and now he’s parking himself in Glastonbury, Connecticut, set...